CO2023005611A2 - Anticuerpos anti-cd47 novedosos y usos de los mismos - Google Patents
Anticuerpos anti-cd47 novedosos y usos de los mismosInfo
- Publication number
- CO2023005611A2 CO2023005611A2 CONC2023/0005611A CO2023005611A CO2023005611A2 CO 2023005611 A2 CO2023005611 A2 CO 2023005611A2 CO 2023005611 A CO2023005611 A CO 2023005611A CO 2023005611 A2 CO2023005611 A2 CO 2023005611A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- novel anti
- hemagglutination
- humans
- therapeutic agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020120869 | 2020-10-14 | ||
| CN2020122188 | 2020-10-20 | ||
| PCT/CN2021/123892 WO2022078465A1 (en) | 2020-10-14 | 2021-10-14 | Novel anti-cd47 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023005611A2 true CO2023005611A2 (es) | 2023-05-29 |
Family
ID=81207683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0005611A CO2023005611A2 (es) | 2020-10-14 | 2023-05-02 | Anticuerpos anti-cd47 novedosos y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230399400A1 (https=) |
| EP (1) | EP4229088A1 (https=) |
| JP (1) | JP2023546277A (https=) |
| KR (1) | KR20230114745A (https=) |
| CN (1) | CN116348601A (https=) |
| AU (1) | AU2021360633A1 (https=) |
| CA (1) | CA3198895A1 (https=) |
| CO (1) | CO2023005611A2 (https=) |
| IL (1) | IL302112A (https=) |
| MX (1) | MX2023004223A (https=) |
| TW (1) | TW202229351A (https=) |
| WO (1) | WO2022078465A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017332960B2 (en) | 2016-10-20 | 2019-09-12 | I-Mab Biopharma Us Limited | Novel CD47 monoclonal antibodies and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017332960B2 (en) * | 2016-10-20 | 2019-09-12 | I-Mab Biopharma Us Limited | Novel CD47 monoclonal antibodies and uses thereof |
| WO2019091473A1 (en) * | 2017-11-10 | 2019-05-16 | I-Mab Biopharma Co., Ltd. | Fusion proteins containing cd47 antibodies and cytokines |
| WO2020036977A1 (en) * | 2018-08-13 | 2020-02-20 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
| AU2019370754A1 (en) * | 2018-10-31 | 2021-02-04 | I-Mab Biopharma Us Limited | Novel CD47 antibodies and methods of using same |
| CA3097443A1 (en) * | 2018-11-12 | 2020-05-22 | I-Mab Biopharma Us Limited | Fusion proteins containing cd47 antibodies and cytokines |
-
2021
- 2021-10-14 AU AU2021360633A patent/AU2021360633A1/en not_active Abandoned
- 2021-10-14 KR KR1020237016071A patent/KR20230114745A/ko not_active Withdrawn
- 2021-10-14 EP EP21879507.8A patent/EP4229088A1/en not_active Withdrawn
- 2021-10-14 US US18/249,054 patent/US20230399400A1/en active Pending
- 2021-10-14 MX MX2023004223A patent/MX2023004223A/es unknown
- 2021-10-14 JP JP2023547735A patent/JP2023546277A/ja not_active Withdrawn
- 2021-10-14 TW TW110138242A patent/TW202229351A/zh unknown
- 2021-10-14 WO PCT/CN2021/123892 patent/WO2022078465A1/en not_active Ceased
- 2021-10-14 CA CA3198895A patent/CA3198895A1/en active Pending
- 2021-10-14 IL IL302112A patent/IL302112A/en unknown
- 2021-10-14 CN CN202180068919.2A patent/CN116348601A/zh active Pending
-
2023
- 2023-05-02 CO CONC2023/0005611A patent/CO2023005611A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022078465A1 (en) | 2022-04-21 |
| KR20230114745A (ko) | 2023-08-01 |
| EP4229088A1 (en) | 2023-08-23 |
| TW202229351A (zh) | 2022-08-01 |
| US20230399400A1 (en) | 2023-12-14 |
| MX2023004223A (es) | 2023-08-03 |
| AU2021360633A9 (en) | 2025-01-09 |
| CA3198895A1 (en) | 2022-04-21 |
| JP2023546277A (ja) | 2023-11-01 |
| IL302112A (en) | 2023-06-01 |
| CN116348601A (zh) | 2023-06-27 |
| AU2021360633A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003085A1 (es) | Anticuerpos contra sars-cov-2 | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| CO2019005033A2 (es) | Anticuerpos monoclonales cd47 novedosos y usos de los mismos | |
| CO2023004252A2 (es) | Anticuerpos anti-ceacam5 y conjugados y usos de los mismos | |
| MX2020001052A (es) | Formulaciones de anticuerpos anti-c5 de alta concentracion. | |
| CO2021003931A2 (es) | Dosis unitaria de vacuna contra el dengue y administración de esta | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| ECSP044933A (es) | Método y montaje para aumentar el volumen del cabello | |
| BR112017023380A2 (pt) | sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo. | |
| CO2023002959A2 (es) | Neoantígenos ras y usos de los mismos | |
| CY1109286T1 (el) | Σκευασμα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου | |
| AR094292A1 (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| CL2020000508A1 (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. | |
| CO2024007220A2 (es) | Compuestos que contienen heteroátomos y usos de estos | |
| CO2023005611A2 (es) | Anticuerpos anti-cd47 novedosos y usos de los mismos | |
| PY2188555A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| CO2024003578A2 (es) | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos | |
| Souza et al. | Endonyx toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye | |
| CO2022007361A2 (es) | Terapia de combinación para el tratamiento de cáncer cerebral | |
| EA202091563A1 (ru) | Человеческие антитела к гемагглютинину вируса гриппа | |
| MX2023007229A (es) | Constructo de arn. | |
| MX2022013632A (es) | Construcciones de union al antigeno dirigidas a her2 y sus usos. |